Decaffeinated coffee prevents scopolamine-induced memory impairment in rats

Behavioural Brain Research

Volumn 245, Issue , 2013, Pages 113-119

  Jang, Young Jin ^a   Kim, Jiyoung ^a,b,c   Shim, Jaesung ^a   Kim, Chang Yul ^d   Jang, Jung Hee ^d   Lee, Ki Won ^a,b,c   Lee, Hyong Joo ^a,b,c  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Daegu Haany University   (South Korea)

Author keywords

Decaffeinated coffee; Memory; NF B; Scopolamine; TNF

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SCOPOLAMINE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COFFEE; COGNITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DECAFFEINATED COFFEE; ENZYME INHIBITION; FOOD INTAKE; MALE; MAZE TEST; MEMORY DISORDER; MENTAL PERFORMANCE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPATIAL LEARNING;

ACTINS; ANIMALS; AVOIDANCE LEARNING; BLOTTING, WESTERN; BRAIN CHEMISTRY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COFFEE; MALE; MAZE LEARNING; MEMORY DISORDERS; MUSCARINIC ANTAGONISTS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE HYDROBROMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875248399     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.02.003     Document Type: Article

References (38)

1. Lindsay J., Laurin D., Verreault R., Hébert R., Helliwell B., Hill G.B., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. American Journal of Epidemiology 2002, 156:445-453.
2. Gelber R.P., Petrovitch H., Masaki K.H., Ross G.W., White L.R. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. Journal of Alzheimer's Disease 2011, 23:607-615.
3. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. Journal of Neuroscience 2001, 21:RC143.
4. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA: The Journal of the American Medical Association 2000, 283:2674-2679.
5. Schwarzschild M.A., Xu K., Oztas E., Petzer J.P., Castagnoli K., Castagnoli N., et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 2003, 61:S55-S61.
6. McCall A.L., Millington W.R., Wurtman R.J. Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. Life Sciences 1982, 31:2709-2715.
7. Canas P.M., Porciuncula L.O., Cunha G.M., Silva C.G., Machado N.J., Oliveira J.M., et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. Journal of Neuroscience 2009, 29:14741-14751.
8. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. Journal of Alzheimer's Disease 2010, 20(Suppl. 1):S95-S116.
9. George S.E., Ramalakshmi K., Rao L.J.M. A perception on health benefits of coffee. Critical Reviews in Food Science and Nutrition 2008, 48:464-486.
10. Hoelzl C., Knasmuller S., Wagner K.H., Elbling L., Huber W., Kager N., et al. Instant coffee with high chlorogenic acid levels protects humans against oxidative damage of macromolecules. Molecular Nutrition and Food Research 2010, 54:1722-1733.
11. Alonso-Salces R.M., Serra F., Remero F., Heberger K. Botanical and geographical characterization of green coffee (Coffea arabica and Coffea canephora): chemometric evaluation of phenolic and methylxanthine contents. Journal of Agricultural and Food Chemistry 2009, 57:4224-4235.
12. Kwon S.H., Lee H.K., Kim J.A., Hong S.I., Kim H.C., Jo T.H., et al. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. European Journal of Pharmacology 2010, 649:210-217.
13. Zhou Y., Fang S.H., Ye Y.L., Chu L.S., Zhang W.P., Wang M.L., et al. Caffeic acid ameliorates early and delayed brain injuries after focal cerebral ischemia in rats. Acta Pharmacologica Sinica 2006, 27:1103-1110.
14. Trinh K., Andrews L., Krause J., Hanak T., Lee D., Gelb M., et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. Journal of Neuroscience 2010, 30:5525-5532.
15. Hwang Y.P., Jeong H.G. The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Letters 2008, 582:2655-2662.
16. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neuroscience and Biobehavioral Reviews 2010, 34:1307-1350.
17. Roncarati R., Scali C., Comery T.A., Grauer S.M., Aschmi S., Bothmann H., et al. Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. Journal of Pharmacology and Experimental Therapeutics 2009, 329:459-468.
18. Griffin R., Nally R., Nolan Y., McCartney Y., Linden J., Lynch M.A. The age-related attenuation in long-term potentiation is associated with microglial activation. Journal of Neurochemistry 2006, 99:1263-1272.
19. Mhatre M., Floyd R.A., Hensley K. Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. Journal of Alzheimer's Disease 2004, 6:147-157.
20. Akiyama H., Arai T., Kondo H., Tanno E., Haga C., Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Disease and Associated Disorders 2000, 14(Suppl. 1):S47-S53.
21. Hauss-Wegrzyniak B., Lynch M.A., Vraniak P.D., Wenk G.L. Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Experimental Neurology 2002, 176:336-341.
22. Fillit H., Ding W., Buee L., Kalman J., Altstiel L., Lawlor B., et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neuroscience Letters 1991, 129:318-320.
23. Cho E.S., Jang Y.J., Hwang M.K., Kang N.J., Lee K.W., Lee H.J. Attenuation of oxidative neuronal cell death by coffee phenolic phytochemicals. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 2009, 661:18-24.
24. Kim J., Lee S., Shim J., Kim H.W., Kim J.K., Jang Y.J., et al. Caffeinated coffee, decaffeinated coffee, and the phenolic phytochemical chlorogenic acid up-regulate NQO1 expression and prevent H(2)O(2)-induced apoptosis in primary cortical neurons. Neurochemistry International 2012, 60:466-474.
25. Ho L., Varghese M., Wang J., Zhao W., Chen F., Knable L.A., et al. Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in mice. Nutritional Neuroscience 2012, 15:37-45.
26. Griffin W.S.T., Jin Gen S., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. Journal of Neuropathology and Experimental Neurology 1995, 54:276-281.
27. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathologica 1995, 89:544-551.
28. Medeiros R., Prediger R.D.S., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., et al. Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein. Journal of Neuroscience 2007, 27:5394-5404.
29. Wang Q., Wu J., Rowan M.J., Anwyl R. β-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. European Journal of Neuroscience 2005, 22:2827-2832.
30. Belarbi K., Jopson T., Tweedie D., Arellano C., Luo W., Greig N.H., et al. TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. Journal of Neuroinflammation 2012, 9:23.
31. Chui M.H., Papanikolaou Y., Fontaine-Bisson B., Turcotte J., Wolever T.M., El-Sohemy A., et al. The TNF-alpha-238G > a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes. Behavioral Neuroscience 2007, 121:619-624.
32. Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., et al. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5219-5223.
33. Tse S.Y. Cholinomimetic compound distinct from caffeine contained in coffee. II: muscarinic actions. Journal of Pharmaceutical Sciences 1992, 81:449-452.
34. Krakauer T. The polyphenol chlorogenic acid inhibits staphylococcal exotoxin-induced inflammatory cytokines and chemokines. Immunopharmacology and Immunotoxicology 2002, 24:113-119.
35. Chao P.C., Hsu C.C., Yin M.C. Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice. Nutrition and Metabolism 2009, 6:33.
36. Chao C.Y., Mong M.C., Chan K.C., Yin M.C. Anti-glycative and anti-inflammatory effects of caffeic acid and ellagic acid in kidney of diabetic mice. Molecular Nutrition and Food Research 2010, 54:388-395.
37. Hackett J., Telepchak M.J., Coyer M.J. Analysis of total caffeine and other xanthines in specialty coffees using mixed mode solid-phase extraction and liquid chromatography-diode-array detection after microwave digestion. Journal of Analytical Toxicology 2008, 32:695-701.
38. Muller C.E., Jacobson K.A. Xanthines as adenosine receptor antagonists. Handbook of Experimental Pharmacology 2011, 200:151-199.